Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice

European Journal of Pharmacology

Volumn 371, Issue 2-3, 1999, Pages 137-145

  De Sarro, Giovambattista ^a   De Sarro, Angela ^b   Di Paola, Eugenio Donato ^a   Bertorelli, Rosalia ^c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Schering Plough Research Institute   (Italy)

Author keywords

Adenosine; Adenosine receptor agonist; Adenosine receptor antagonist; Adenosine receptor subtype; DBA 2 mice; Epilepsy; Seizure audiogenic

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3 CHLOROSTYRYL)CAFFEINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; CAFFEINE; RECEPTOR SUBTYPE; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

ANIMALS; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, INBRED DBA; NOISE; RECEPTORS, PURINERGIC P1; SEIZURES;

EID: 0032956116     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00132-6     Document Type: Article

References (65)

1. Adami M., Bertorelli R., Ferri N., Foddi M.C., Ongini E. Effects of repeated administration of selective adenosine A1 and A (2A) receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur. J. Pharmacol. 294:1995;383-389.
2. Albertson T.E., Stark L.G., Joy R.M., Bowyer J.F. Aminophylline and kindled seizures. Exp. Neurol. 81:1983;703-713.
3. Ault B., Wang C.M. Adenosine inhibits epileptiform activity arising in hippocampal area CA3. Br. J. Pharmacol. 87:1986;695-703.
4. Baraldi P.G., Manfredini S., Simoni D., Zappaterra L., Zocchi C., Dionisotti S., Ongini E. Synthesis of new pyrazolo(4,3-e)1,2,4-triazolo(1,5-c) pyrimidine and 1,2,3-triazolo(4,5-e)1,2,4-triazolo(1,5-c) pyrimidine displaying potent and selective activity as A(2a) adenosine receptor antagonists. Bioorg. Med. Chem. Lett. 4:1994;2539-2544.
5. Bertorelli R., Ferri N., Adami M., Ongini E. Effects of selective agonists and antagonists for A1 or A(2A) adenosine receptors on sleep-waking patterns in rats. Drug Dev. Res. 37:1996;65-72.
6. 6-2-(4-aminophenyl)ethyl-adenosine enhances the anticonvulsive activity of antiepileptic drugs. Eur. J. Pharmacol. 327:1997;125-133.
7. Bowker H.M., Chapman A. Adenosine analogues. The temperature-dependence of the anticonvulsant effect and inhibition of 3H-D-aspartate release. Biochem. Pharmacol. 35:1986;2949-2953.
8. Chapman A.G., Croucher M.J., Meldrum B.S. Evaluation of anticonvulsant drugs in DBA/2 mice with sound-induced seizures. Arzneim.-Forsch. Drug Res. 34:1984;1261-1264.
9. Chapman A.G., De Sarro G., Premachandra M., Meldrum B.S. Bidirectional effects of beta-carbolines in reflex epilepsy. Brain Res. Bull. 19:1987;337-346.
10. Chu N.S. Caffeine- and aminophylline-induced seizures. Epilepsia. 22:1981;85-94.
11. Cunha R.A., Milusheva E., Vizi E.S., Ribeiro J.A., Sebastiao A.M. Excitatory and inhibitory effects of A1 and A2A adenosine receptor activation on the electrically evoked (3H)acetylcholine release from different areas of the rat hippocampus. J. Neurochem. 63:1994;207-214.
12. Cutrufo C., Bortot L., Giachetti A., Manzini S. Different effects of various xanthines on pentylenetetrazole-induced seizures in rats: an EEG and behavioural study. Eur. J. Pharmacol. 222:1992;1-6.
13. Czuczwar S.J., Janusz W., Wamil A., Kleinrok Z. Inhibition of aminophylline-induced convulsions in mice by antiepileptic drugs and other agents. Eur. J. Pharmacol. 144:1987;309-315.
14. Daval J.L., Nehlig A., Nicolas F. Physiological and pharmacological properties of adenosine: therapeutic implications. Life Sci. 49:1991;1435-1453.
15. De Sarro G., Meldrum B.S., Nisticò G. Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br. J. Pharmacol. 93:1988;247-256.
16. De Sarro G.B., De Sarro A., Meldrum B.S. Anticonvulsant action of 2-chloroadenosine injected focally into the inferior colliculus and substantia nigra. Eur. J. Pharmacol. 194:1991;145-152.
17. De Sarro G., Ongini E., Bertorelli R., Aguglia U., De Sarro A. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur. J. Pharmacol. 262:1994;11-19.
18. De Sarro G.B., Ammendola D., Nava F., De Sarro A. Effects of some excitatory amino acid antagonists on imipenem-induced seizures in DBA/2 mice. Brain Res. 671:1995;131-140.
19. De Sarro A., Naccari F., Imperatore C., De Sarro G.B. Comparative convulsant potencies of two monobactam derivatives in C57, Swiss and DBA/2 mice. J. Antimicrob. Chemother. 38:1996;475-484.
20. 1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene. Eur. J. Pharmacol. 317:1996;239-245.
21. De Sarro A., Grasso S., Zappalà M., Nava F., De Sarro G.B. Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;48-55.
22. 2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models. Br. J. Pharmacol. 112:1994;659-665.
23. Dragunow M., Robertson H.A. 8-Cyclopentyl-1,3-dimethylxanthine prolongs epileptic seizures in rats. Brain Res. 417:1987;377-379.
24. Dragunow M., Goddard G.V., Laverty R. Is adenosine an endogenous anticonvulsant? Epilepsia. 26:1985;480-487.
25. Dunwiddie T.V. Endogenously released adenosine regulates excitability in the in vitro hippocampus. Epilepsia. 21:1980;541-548.
26. Dunwiddie T.V. The physiological role of adenosine in the central nervous system. Int. Rev. Neurobiol. 27:1985;63-139.
27. Dunwiddie T.V., Worth T. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J. Pharmacol. Exp. Ther. 220:1982;70-76.
28. During M.J., Spencer D.D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 32:1992;618-624.
29. Engstrom F.L., Woodbury D.M. Seizure susceptibility in DBA and C57 mice: the effects of various convulsants. Epilepsia. 29:1988;389-395.
30. (2A) receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 321:1997;143-147.
31. Francis A., Fochtmann L. Caffeine augmentation of electroconvulsive seizures. Psychopharmacology (Berlin). 115:1994;320-324.
32. Fredholm B.B. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol. Toxicol. 76:1995;93-101.
33. Fredholm B.B., Abbracchio M.P., Burnstook G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M. VI. Nomenclature and classification of puriniceptors. Pharmacol. Rev. 46:1994;143-156.
34. 2-adenosine antagonist in vitro and in vivo. FEBS Lett. 323:1993;141-144.
35. Jacobson K.A., Kim H.O., Siddiqi S.M., Olah M.E., Stiles G.L., Von Lubitz D.K.J.E. A3 adenosine receptors: design of selective ligands and therapeutic prospects. Drugs Future. 20:1995;689-699.
36. Janusz C.A., Berman R.F. The A2-selective adenosine analog, CGS 21680, depresses locomotor activity but does not block amygdala kindled seizures in rats. Neurosci. Lett. 141:1992;247-250.
37. Kanda T., Shiozaki S., Shimada J., Suzuki F., Nakamura J. KF 17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 256:1994;263-268.
38. Karton Y., Jiang J.L., Ji X.D., Melman N., Olah M.E., Stiles G.L., Jacobson K.A. Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J. Med. Chem. 39:1996;2293-2301.
39. Klitgaard H., Knutsen L.J., Thomsen C. Contrasting effects of adenosine A1 and A2 receptor ligands in different chemoconvulsive rodent models. Eur. J. Pharmacol. 242:1993;221-228.
40. 2a receptor. Nature. 388:1997;674-678.
41. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Ther. 96:1949;99-111.
42. Maitre M., Chesielski L., Lehmann A., Kempf E., Mandel P. Protective effect of adenosine and nicotinamide against audiogenic seizure. Biochem. Pharmacol. 23:1974;2807-2816.
43. Malhotra J., Gupta Y.K. Effect of adenosine receptor modulation on pentyleneterazole-induced seizures in rats. Br. J. Pharmacol. 120:1997;282-288.
44. Monopoli A., Conti A., Zocchi C., Casati C., Volpini R., Cristalli G., Ongini E. Pharmacology of the new selective A(2a) adenosine receptor agonist 2-hexynyl-5′-N-ethylcarboxamidoadenosine. Arzneim.-Forsch. Drug Res. 44:1994;1296-1304.
45. Muller C.E., Stein B. Adenosine receptor antagonists: structures and potential therapeutic applications. Current Pharmaceutical Design. 2:1996;501-530.
46. Nehlig A., Daval J.L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Rev. 17:1992;139-170.
47. Nikodijevic O., Daly J.W., Jacobson K.A. Characterization of the locomotor depression produced by an A2-selective agonist. FEBS Lett. 261:1990;67-70.
48. Ongini E., Fredholm B.B. Pharmacology of adenosine A(2A) receptors. Trends Pharmacol. Sci. 17:1996;364-372.
49. Ribeiro, J.A., 1991. Purinergic regulation of transmitter release. In: Phillis, J.W. (Ed.), Adenosine and Adenine Nucleotides as Regulators of Cellular Function. CRC Press, Boca Raton, pp. 155-161.
50. Sanders R.C., Murray T.F. Temporal relationship between A1 adenosine receptor upregulation and alterations in bicuculline seizure susceptibility in rats. Neurosci. Lett. 101:1989;325-330.
51. Seyfried T.N., Glaser G.H. A review of mouse mutants as genetic models of epilepsy. Epilepsia. 26:1985;143-150.
52. Stone, T.W., Collins, M.G., Williams, M., Miller, L.P., Karasawa, A., Hillaire-Buys, D., 1995. Adenosine: some therapeutic applications and prospects. In: Cuello, A.C., Coller, B. (Eds.), Perspectives for Research and Therapy in the Late 1990s. Birkhauser Verlag, Basel, pp. 303-309.
53. 2 adenosine receptors. Life Sci. 39:1986;743-750.
54. Van Rhee A.M., Jiang J.L., Melman N., Olah M.E., Stiles G.L., Jacobson K.A. Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. J. Med. Chem. 39:1996;2980-2989.
55. Virus R.M., Ticho S., Pilditch M., Radulowacki M. A comparison of the effects of caffeine, 8-cyclopentyltheophylline, and alloxazine on sleep in rats. Possible roles of central nervous system adenosine receptors. Neuropsychopharmacology. 3:1990;243-249.
56. 6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice. Eur. J. Pharmacol. 249:1993;265-270.
57. Von Lubitz D.K.J.E., Carter M.F., Beenhakker M., Lin R.C.S., Jacobson K.A. Adenosine: a prototherapeutic concept in neurodegeneration. Ann. N.Y. Acad. Sci. 765:1995;163-178. discussion 196-197.
58. Von Lubitz D.K.J.E., Carter M.F., Deutsch S.I., Lin R.C.S., Mastropaolo J., Meshulam Y., Jacobson K.A. The effects of adenosine A3 receptor stimulation on seizures in mice. Eur. J. Pharmacol. 275:1995;23-29.
59. Walker J.E. Effect of aminophylline on seizure thresholds and brain regional cyclic nucleotides in the rat. Exp. Neurol. 74:1981;299-304.
60. Williams M., Francis J., Ghai G., Braunwalder A., Psychoyos S., Stone G.A., Cash W.D. Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist. J. Pharmacol. Exp. Ther. 241:1987;415-420.
61. Young D., Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience. 58:1994;245-261.
62. Zhang G., Franklin P.H., Murray T.F. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J. Pharmacol. Exp. Ther. 264:1993;1415-1424.
63. Zhang G., Franklin P.H., Murray T.F. Activation of adenosine A1 receptors underlies anticonvulsant effect of CGS21680. Eur. J. Pharmacol. 255:1994;239-243.
64. 2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;398-404.
65. Zwillich C.W., Sutton F.D., Neff T.A., Cohn W.M., Matthay R.A., Weinberger M.M. Theophylline-induced seizures in adults. Correlation with serum concentrations. Ann. Intern. Med. 82:1975;784-787.